Friday, Sept. 12 | 11 a.m.–3 p.m. ET 
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for lung cancer. FREE for healthcare professionals, students, patients and patient advocates.

New for 2025

  • Manage non-small cell lung cancer in the perioperative, metastatic, and second-line settings.
  • Discuss a wide range of case studies, including managing toxicities associated with the bispecific tarlatamab for small cell lung cancer and understand treating immune-related toxicities when corticosteroids do not work.
The 2025 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, GSK, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., and Replimune Inc. (supporters as of Apr. 1, 2025).

Program Organizers

Marina Garassino, MD

Marina Garassino, MD
University of Chicago

Lizza Hendriks, MD, PhD

Lizza Hendriks, MD, PhD
Universiteit Maastricht

Daniel Morgensztern, MD

Daniel Morgensztern, MD
Washington University in St. Louis

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours
Program Date & Location
Friday, September 12 at 11 a.m. – 3 p.m. ET
Live via Zoom Webinar
Program Cost
FREE for healthcare professionals, students, patients and patient advocates.
Register for A Focus on Lung Cancers >

“This is an excellent program for practicing clinicians. I would say a "must attend" for anyone treating lung cancer.”

- Previous ACI Attendee

Program Agenda

11:00–11:05 a.m.

 

Welcome and Relevant SITC Resources

11:05–11:35 a.m.

 

Immunotherapy-based Treatments for Small Cell Lung Cancer
Daniel Morgensztern, MD – Washington University in St. Louis

11:35a.m.–12:05 p.m.

  

Perioperative Treatment of Non-Small Cell Lung Cancer
Jamie Chaft, MD – Memorial Sloan Kettering Cancer Center

12:05–12:35 p.m.

 

Immunotherapy for Non-Resectable Stage 3 Lung Cancer
Francesco Cortiula, PHD - Universiteit Maastricht, Netherlands

12:35–1:05 p.m.

 

Immunotherapy-based Second-Line Treatments for Non-Small Cell Lung Cancer
Marina Garassino, MD – University of Chicago

1:05–1:20 p.m.

 

Break

1:20–2 p.m.

 

Cancer Immunotherapy In Practice: Treating Immune-Related Toxicities When Corticosteroids Don’t Work
Jarushka Naidoo, MBBCh, MHS – Royal College of Surgeons in Ireland

2–2:20 p.m.

 

Faculty Panel: Case Study on Small Cell Lung Cancer, Tarlatamab, ICANS/CRS
Misty Shields, MD, PhD – Indiana University

2:20–2:40 p.m

 

Faculty Panel: Case Study on Stage 2 Non-Small Cell Lung Cancer, Perioperative Treatment
Charu Aggarwal, MD, MPH – University of Pennsylvania

2:40–3 p.m

 

Faculty Panel: Case Study on Stage 4 Disease, PD-L1 Negative
Kaushal Parikh, MD – Mayo Clinic

3 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2025 ACI series.


Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of lung cancers for key disease states.
  • Summarize recent updates in cancer immunotherapy for lung cancers including emerging toxicities and management.
  • Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
  • Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer (SITC).  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

Partners designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Partners designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosures and ADA Info

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

SITC's Clinical Practice Guideline (CPG) Resources

Find information regarding disease-specific treatment algorithms and recommended administration of FDA-approved cancer immunotherapies. The guidelines are reviewed by expert panels on a recurring basis to account for newly available clinical trial data and FDA approvals.

 Relevant Guidelines

 Mini-Modules

 Featured Webinars

The 2025 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.